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To celebrate the
25 years of TCT,
the organizers
produced
a compelling
opening ceremony. It
focused on the birth
of interventional
cardiology and the
father of the
subspecialty,
Andreas Gruentzig.The Transcatheter Cardiovascular Therapeutics (TCT) meeting has just wrapped up, and it will be
remembered not so much for scientiﬁc breakthroughs but for the extensive reﬂection on the
developments of the specialty of interventional cardiology. Because this was the 25th anniversary of
the TCT meeting, there were numerous presentations and panels involving us old guys (some
would say “old fds”) who have been around for the past 30-plus years. It is said that we should
study history so as not to risk repeating it. As I listened to my colleagues expound and perhaps
“expand” on tales of the early days, I could detect a sense of nostalgia, but no one would want to
repeat the tribulations of the days of angioplasty before stent implantation. It is instructive for the
younger practitioners of our profession to hear that stent placement transformed coronary
interventions not just because it reduced restenosis. This was, of course, a frequent occurrence but
not such a severe problem after balloon angioplasty. No, the transformation was primarily because
it eliminated the dreaded acute occlusion of the artery leading to middle-of-the-night calls back to
the catheterization lab or to emergency surgery.
To celebrate the 25 years of TCT, the organizers produced a compelling opening ceremony.
It focused on the birth of interventional cardiology and the father of the subspecialty, Andreas
Gruentzig. Marty Leon and Gregg Stone conceived the idea of bringing together many of the early
contributors and, from old ﬁlm footage, compiled an emotional video presentation highlighting
the birth and beginnings. Marty asked me to invite some of Andreas’s family, and we were
honored to have his ﬁrst wife, Michaela, and his 2 daughters come with Gail and me to San
Francisco. When Sonja, a professional actress in Berlin, responded to the presentation of the
Lifetime Achievement Award posthumously to her father, she said, “Hello, my name is Sonja
Gruentzig, and I would like to introduce myself as the twin of the balloon catheter. For as my
mother was pregnant with me, my father was pregnant with the balloon catheter. We both hatched
in the same hospital in Zurich, and were even brought up at the same kitchen table. So as you may
see, we both have thrived and matured over the past 37 years. My mother, Michaela, my sister,
Katrin, and I want to thank you for your kind invitation to San Francisco and are honored to
receive the award in the name of Andreas Gruentzig.”
The family members who are not bombarded with angioplasty history in Zurich or Berlin were
truly touched by the outpouring of gratitude that many expressed for Andreas’s seminal
contributions to so many lives, be they patients or practitioners.
Somewhat forgotten in the fog of history is how insightful Andreas was about future
developments in endovascular therapy. At TCT, stories were told about how he experimented with
plaque-removing methods even before the balloon, his opinion of early versions of the stent,
and his prediction of a catheter-delivered aortic valve. But the history lessons did not stop with
Gruentzig or the early developers of many devices, or the expansion of interventions to more
complex anatomy and clinical presentations, especially acute myocardial infarction and the now
rapidly growing attack on structural heart disease. There were stories of technical developments,
patent ﬁghts won and lost, and many personal recollections, in the formal sessions and afterward.
There were also a number of clinical trials reported, and as with other recent meetings, many
of them seemed to offer negative or neutral results. More interesting were the reports of new
technology or variations in current devices aimed at solving some of the current problems of our
subspecialty. In some of these, I see a need to revisit our history to learn about what worked and
what did not. One area in which we may be headed back to the future is obstructive coronary artery
disease, the ﬁrst frontier for interventional cardiology. The saga of the balloon evolving to the stent
and then to the drug-eluting stent is well known. Now we may be heading toward eliminating the
stent and returning to a healed artery, with no residual foreign body. The concept of biodegradable
stents is so seductive that I learned that some operators in Germany are now using the
bioabsorbable scaffold in 90% of patients. Of course, we have no evidence that it is better or
worse than drug-eluting metal stents, but this direction, as well as drug-eluting balloons, without
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1331any scaffold, and perhaps other methods to modify
the healing process may bring us back to what
Gruentzig tried the ﬁrst time around.Without evidence
of how the healing of dilated coronary obstructions
would work out, balloon dilation was developed,
opening the obstruction and then letting nature take its
course as the “wound”healed.Many times it even healed
open.
Bernie Meier recounted the story of Mr. Bachman,
the ﬁrst angioplasty patient. After Gruentzig opened
the artery, the angina was completely relieved. Ten
years later, at a 1987 Emory demonstration course,
I performed coronary arteriography on Mr. Bachman
and found wide patency of the healed left anterior
descending coronary artery. In 2000, he reported some
symptoms, and Bernie performed another catheteri-
zation. Even though the artery was open, recurrent
symptoms caused Mr. Bachman to press the issue,
resulting in another catheterization, with ambiguous
angiographic results. Bachman insisted that he wanted
a stent and was sure that this was now needed, as he
had followed the evolution of the specialty and knewthat he had undergone only balloon angioplasty.
The stent was implanted; however, 3 months later,
Bachman stated that he now had clear-cut effort
angina as bad as he had initially in 1977. Repeat
catheterization showed severe restenosis, which Bernie
treated with balloon angioplasty, and Mr. Bachman
has remained asymptomatic ever since. A take-home
message could be that balloon angioplasty worked for
23 years, bare-metal stenting worked for 3 months,
and repeat balloon angioplasty has now worked for
another 13 years. As amusing as this is, we do not
draw this conclusion, but neither should we blindly
accept that the current technologies are the only and
ultimate solutions. Remembering lessons of the past
may enable more progress in the future.Address correspondence to:
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